{"generic":"Levobupivacaine Hydrochloride","drugs":["Levobupivacaine Hydrochloride"],"mono":{"0":{"id":"925157-s-0","title":"Generic Names","mono":"Levobupivacaine Hydrochloride"},"1":{"id":"925157-s-1","title":"Dosing and Indications","sub":{"0":{"id":"925157-s-1-4","title":"Adult Dosing","mono":"<ul><li>Levobupivacaine marketed in the United States under the brand name Chirocaine(R) was discontinued on 9\/30\/2003.<\/li><li><b>Local anesthesia:<\/b> retrobulbar anesthesia, 5 mL of 0.5% solution<\/li><li><b>Local anesthesia:<\/b> local anesthetic, 60 mL of 0.25% solution (150 mg)<\/li><li><b>Obstetric pain:<\/b> 10 to 20 mL of 0.25% solution EPIDURAL bolus (25 to 50 mg)<\/li><li><b>Postoperative pain:<\/b> 4 to 10 mL\/hr of 0.125% or 0.25% solution EPIDURAL infusion (5 to 25 mg\/hour); 0.125% used only in combination with fentanyl or clonidine<\/li><li><b>Regional anesthesia:<\/b> peribulbar infiltration, 5 to 15 mL of 0.75% solution (37.5 to 112.5 mg)<\/li><li><b>Regional anesthesia:<\/b> peripheral block, 30 mL or 0.4 mL\/kg of 0.25% to 0.5% solution (75 to 150 mg (1 to 2 mg\/kg))<\/li><li><b>Regional anesthesia:<\/b> epidural (surgical), 10 to 20 mL of 0.5 to 0.75% solution (50 to 150 mg)<\/li><li><b>Regional anesthesia:<\/b> epidural (cesarean section) 20 to 30 mL of 0.5% solution (100 to 150 mg)<\/li><\/ul>"},"1":{"id":"925157-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>Levobupivacaine marketed in the United States under the brand name Chirocaine(R) was discontinued on 9\/30\/2003.<\/li><li>safety and effectiveness not established in pediatric patients<\/li><\/ul>"},"3":{"id":"925157-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Levobupivacaine marketed in the United States under the brand name Chirocaine(R) was discontinued on 9\/30\/2003.<\/li><li>Local anesthesia<\/li><li>Obstetric pain<\/li><li>Postoperative pain<\/li><li>Regional anesthesia<\/li><\/ul>"}}},"3":{"id":"925157-s-3","title":"Contraindications\/Warnings","sub":[{"id":"925157-s-3-9","title":"Contraindications","mono":"<ul><li>hypersensitivity to amide local anesthetics<\/li><li>hypersensitivity to levobupivacaine, or bupivacaine<\/li><\/ul>"},{"id":"925157-s-3-10","title":"Precautions","mono":"<ul><li>avoid 0.75% solution in obstetrical patients<\/li><li>avoid unintended intravenous injection; may result in cardiovascular arrest and prolonged resuscitation<\/li><li>avoid unintended intravascular or intrathecal injection during epidural administration; may lead to high plasma level or very high spinal anesthesia resulting in apnea, severe hypotension, or loss of consciousness<\/li><li>not recommended for emergency situations where fast onset of surgical anesthesia is necessary<\/li><li>should not be used in intravenous regional anesthesia (Bier block); risk of reaching toxic blood levels<\/li><li>should not be used in production of obstetrical paracervical block anesthesia; additional risk of fetal bradycardia and death<\/li><li>hypotensive patients or those with cardiovascular disease, especially heart block<\/li><li>infection at injection site<\/li><li>injections in head and neck area; may produce adverse reactions similar to unintentional large doses of intravascular injection<\/li><li>liver disease or conditions associated with reduced hepatic blood flow<\/li><li>patient receiving other local anesthetics<\/li><li>peripheral nerve block using large volumes of higher concentrations of levobupivacaine; increased risk of dose-related cardiac toxicity<\/li><li>repeated injections may cause significant increases in plasma levels<\/li><\/ul>"},{"id":"925157-s-3-11","title":"Pregnancy Category","mono":"Levobupivacaine: B (FDA)<br\/>"},{"id":"925157-s-3-12","title":"Breast Feeding","mono":"<ul><li>Levobupivacaine: AAP: Drugs for which the effect on nursing infants is unknown but may be of concern.<\/li><li>Levobupivacaine: Micromedex: Infant risk is minimal.<\/li><\/ul>"}]},"4":{"id":"925157-s-4","title":"Drug Interactions","sub":{"1":{"id":"925157-s-4-14","title":"Major","mono":"<ul>St John's Wort (probable)<\/ul>"}}},"5":{"id":"925157-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Pruritus<\/li><li><b>Gastrointestinal:<\/b>Nausea, Vomiting<\/li><li><b>Neurologic:<\/b>Dizziness<\/li><li><b>Other:<\/b>Fever<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Cardiac arrest, Cardiac dysrhythmia, Hypotension (31%)<\/li><li><b>Respiratory:<\/b>Apnea<\/li><\/ul>"},"6":{"id":"925157-s-6","title":"Drug Name Info","sub":{"2":{"id":"925157-s-6-19","title":"Class","mono":"<ul><li>Amino Amide<\/li><li>Anesthetic, Local<\/li><\/ul>"},"3":{"id":"925157-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"}}},"10":{"id":"925157-s-10","title":"Monitoring","mono":"<ul><li>blood pressure, heart rate, muscle twitching, peripheral nerve stimulation<\/li><li>blood gases, ECG, respirations<\/li><li>signs of CNS toxicity<\/li><\/ul>"},"13":{"id":"925157-s-13","title":"Clinical Teaching","mono":"<ul><li>This drug may cause nausea, vomiting, dizziness, or fever.<\/li><li>Instruct patients receiving spinal or epidural bupivacaine to report signs\/symptoms of respiratory paralysis (high spinal effects), muscle weakness, hypotension, or urinary retention.<\/li><li>Warn patients receiving all routes of bupivacaine to report signs\/symptoms of unintended IV or intrathecal injections which include CNS or cardiovascular toxicity.<\/li><\/ul>"}}}